Format

Send to

Choose Destination
Med Sci (Paris). 2010 Nov;26(11):969-75. doi: 10.1051/medsci/20102611969.

[Typhoid fever: facing the challenge of resistant strains].

[Article in French]

Author information

1
Institut Pasteur, Centre national de référence des Salmonella, unité des bactéries pathogènes entériques, 28 rue du docteur Roux, Paris cedex 15, France. fxweill@pasteur.fr

Abstract

The introduction of chloramphenicol in 1948 revolutionised the outcome of typhoid fever but chloramphenicol-resistant strains of Salmonella enterica serotype Typhi were reported just two years later. Resistance followed also the introduction of ampicillin and co-trimoxazole. During the second half of the 1980s, strains resistant to the three first-line antimicrobial agents, chloramphenicol, ampicillin and co-trimoxazole emerged and spread rapidly throughout the Indian subcontinent and South East Asia. During the 1990s when fluoroquinolones had become a first-line treatment for typhoid fever, these multi drug resistant (MDR) strains acquired an additional resistance to nalidixic acid with decreased susceptibilities to ciprofloxacin (CIPDS) (MIC range, 0.125-1 mg/l). Considerable data have now accumulated to suggest that infections due to CIPDS strains may not respond satisfactorily to therapy with ciprofloxacin or ofloxacin. Furthermore, identification of such CIPDS strains in clinical laboratories is not easy without determination of MIC of ciprofloxacin. Recently, several isolates highly resistant to ciprofloxacin or to extended-spectrum cephalosporins of Asian origin have been reported.

PMID:
21106179
DOI:
10.1051/medsci/20102611969
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center